Stem cell models of TAFAZZIN deficiency reveal novel tissue-specific pathologies in Barth syndrome
Human Molecular Genetics · 2025
DOI: 10.1093/hmg/ddae152 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Molecular Genetics, 2025. Verfasst von Olivia Sniezek Carney und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetic Medicine, Johns Hopkins University School of Medicine, 733 North Broadway, Baltimore, MD 21205, United States. Hauptthemen laut MEDLINE: Barth Syndrome, Transcription Factors. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS, Maryland TEDCO, NIGMS NIH HHS.
Abstract (Originalsprache)
Barth syndrome (BTHS) is a rare mitochondrial disease caused by pathogenic variants in the gene TAFAZZIN, which leads to abnormal cardiolipin (CL) metabolism on the inner mitochondrial membrane. Although TAFAZZIN is ubiquitously expressed, BTHS involves a complex combination of tissue specific phenotypes including cardiomyopathy, neutropenia, skeletal myopathy, and growth delays, with a relatively minimal neurological burden. To understand both the developmental and functional effects of TAZ-deficiency in different tissues, we generated isogenic TAZ knockout (TAZ-KO) and WT cardiomyocytes (CMs) and neural progenitor cells (NPCs) from CRISPR-edited induced pluripotent stem cells (iPSCs). In TAZ-KO CMs we discovered evidence of dysregulated mitophagy including dysmorphic mitochondria and mitochondrial cristae, differential expression of key autophagy-associated genes, and an inability of TAZ-deficient CMs to properly initiate stress-induced mitophagy. In TAZ-deficient NPCs we identified novel phenotypes including a reduction in CIV abundance and CIV activity in the CIII2&CIV2 intermediate complex. Interestingly, while CL acyl chain manipulation was unable to alter mitophagy defects in TAZ-KO CMs, we found that linoleic acid or oleic acid supplementation was able to partially restore CIV abundance in TAZ-deficient NPCs. Taken together, our results have implications for understanding the tissue-specific pathology of BTHS and potential for tissue-specific therapeutic targeting. Moreover, our results highlight an emerging role for mitophagy in the cardiac pathophysiology of BTHS and reveal a potential neuron-specific bioenergetic phenotype.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Genetic Medicine, Johns Hopkins University School of Medicine, 733 North Broadway, Baltimore, MD 21205, United States.
- Institute of Human Genetics, Medical University of Innsbruck, Peter-Mayr-Str. 1/1.OG, Innsbruck 6020, Austria.
- Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, 615 North Wolfe Street, Baltimore, MD 21205, United States.
ORCID-Profile: Olivia Sniezek Carney, Hilary J Vernon
Förderung
- NIGMS
- Maryland TEDCO
- NIGMS NIH HHS
- National Heart, Lung, and Blood Institute of the National Institutes of Health
- NHLBI NIH HHS
Zitieren
APA
Sniezek Carney, O., Harris, K. W., Wohlfarter, Y., Lee, K., Butschek, G., Anzmann, A. F., Hamacher-Brady, A., Keller, M. A., & Vernon, H. J. (2025). Stem cell models of TAFAZZIN deficiency reveal novel tissue-specific pathologies in Barth syndrome. Human Molecular Genetics. https://doi.org/10.1093/hmg/ddae152
Vancouver
Sniezek Carney O, Harris KW, Wohlfarter Y, Lee K, Butschek G, Anzmann AF, et al. Stem cell models of TAFAZZIN deficiency reveal novel tissue-specific pathologies in Barth syndrome. Human Molecular Genetics. 2025. doi:10.1093/hmg/ddae152
BibTeX
@article{SniezekCarney2025,
author = {Sniezek Carney, Olivia and Harris, Kodi W and Wohlfarter, Yvonne and Lee, Kyuna and Butschek, Grant and Anzmann, Arianna F and Hamacher-Brady, Anne and Keller, Markus A and Vernon, Hilary J},
title = {Stem cell models of TAFAZZIN deficiency reveal novel tissue-specific pathologies in Barth syndrome},
journal = {Human Molecular Genetics},
year = {2025},
doi = {10.1093/hmg/ddae152}
}
EUVIMED